Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com ...

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day ...

Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx management will present ...

CAMBRIDGE, Mass., February 10, 2025--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that Amylyx management ...

February 10, 2025 • Elon Musk's Department of Government Efficiency is quickly expanding its reach through the federal government. January 25, 2025 • A Food and Drug Administration project to ...

After hours: February 12 at 5:06:16 PM EST Loading Chart for AMLX ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that Amylyx management will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference.